TrialBMC pulmonary medicine2017

Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosis-an interim analysis of results from a prospective, single-center, randomized, parallel-group study.

Yosuke Tanaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.